The long-standing toxicological paradigm has characterized the primary metabolites of Bisphenol A (BPA)—specifically Bisphenol A Glucuronide (BPA-G) and Bisphenol A Sulfate (BPA-S)—as harmless, biologically inert compounds. This “detoxification” model, rooted in early pharmacokinetic studies, is now recognized as a significant over-simplification. Contemporary evidence demonstrates that these Phase II conjugates are not terminal waste products; they can enter cells via solute carriers, exert direct biological effects on adipogenesis, and undergo localized enzymatic deconjugation. By regenerating free BPA via beta-glucuronidase and steroid sulfatase, these metabolites act as a latent reservoir of endocrine-disrupting activity, particularly within the vulnerable fetal-placental unit.
Perdue et al. (Sun,) studied this question.